---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Subcutaneous immunoglobulin"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Subcutaneous immunoglobulin. Topics: Guideline recommendation for maintenance treatment, Weekly subcutaneous immunoglobulin versus placebo: relapse or withdrawal over 24 weeks, Facilitated subcutaneous immunoglobulin versus placebo: relapse over 6 months, Long-term facilitated subcutaneous immunoglobulin extension: relapse and tolerability, and 2 further topics. 6 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/subcutaneous-immunoglobulin"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Subcutaneous immunoglobulin

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Subcutaneous Immunoglobulin

<a id="topic-2.2.2.1.3-1"></a>

### Guideline recommendation for maintenance treatment

> “(d) for maintenance treatment, IVIg, subcutaneous immunoglobulin or corticosteroids are recommended”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

<a id="topic-2.2.2.1.3-2"></a>

### Weekly subcutaneous immunoglobulin versus placebo: relapse or withdrawal over 24 weeks

> “We randomly allocated participants to 0·2 g/kg or 0·4 g/kg of a 20% SCIg solution (IgPro20) weekly versus placebo (2% human albumin solution) for maintenance treatment for 24 weeks.”
> “In the intention-to-treat set, 36 (63% [95% CI 50-74]) patients on placebo, 22 (39% [27-52]) on low-dose SCIg, and 19 (33% [22-46]) on high-dose SCIg had a relapse or were withdrawn from the study for other reasons (p=0·0007).”
> “Absolute risk reductions were 25% (95% CI 6-41) for low-dose versus placebo (p=0·007), 30% (12-46) for high-dose versus placebo (p=0·001), and 6% (-11 to 23) for high-dose versus low-dose (p=0·32).”
> “Causally related adverse events occurred in 47 (27%) patients (ten [18%] in the placebo group, 17 [30%] in the low-dose group, and 20 [34%] in the high-dose group).”

Source: [van Schaik et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29122523/)

<a id="topic-2.2.2.1.3-3"></a>

### Facilitated subcutaneous immunoglobulin versus placebo: relapse over 6 months

> “fSCIG 10% was administered at the same dose (or matching placebo volume) and interval as pre-randomization IVIG.”
> “CIDP relapse was reduced with fSCIG 10% versus placebo (n = 6 [9.7%; 95% confidence interval 4.5%, 19.6%] vs n = 22 [31.4%; 21.8%, 43.0%], respectively; absolute difference: -21.8% [-34.5%, -7.9%], p = .0045).”
> “Adverse events (AEs) were more frequent with fSCIG 10% (79.0% of patients) than placebo (57.1%), but severe (1.6% vs 8.6%) and serious AEs (3.2% vs 7.1%) were less common.”

Source: [Bril et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37314318/)

<a id="topic-2.2.2.1.3-4"></a>

### Long-term facilitated subcutaneous immunoglobulin extension: relapse and tolerability

> “The study provided 220 patient‐years of follow‐up data from 85 patients. Median (range) exposure was 33 (0–77) months. Patients received fSCIG every 4 weeks (88.2%) or every 3 weeks (11.8%).”
> “Relapse occurred in 10 of 77 patients (13.0%); annual relapse rate was 4.5%.”
> “fSCIG‐related AEs ( n = 798) included infusion site reactions such as pain, redness, and pruritus.”

Source: [Hadden et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625974/)

<a id="topic-2.2.2.1.3-5"></a>

### Pooled randomized evidence for subcutaneous immunoglobulin

> “Four RCTs with 360 randomised participants met our eligibility criteria.”
> “SCIg maintenance treatment probably reduces the risk of clinically significant deterioration in disability within 12 to 24 weeks compared to placebo (RR 0.40, 95% CI 0.28 to 0.56; 3 studies, 333 participants; moderate‐certainty evidence).”
> “We could not evaluate the difference between SCIg and IVIg as induction treatment in terms of rate of improvement in disability, change in grip strength, or frequency of local or systemic adverse effects, as these data were not available.”

Source: [Bus et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13459082/)

<a id="topic-2.2.2.1.3-6"></a>

### FDA-approved subcutaneous immunoglobulin products for CIDP: indications and dosing

> “HIZENTRA is indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.”
> “Initiate therapy with HIZENTRA 1 week after the last IGIV infusion.”
> “Recommended subcutaneous dose is 0.2 g/kg (1 mL/kg) body weight per week.”

Source: [Hizentra prescribing information (2021)](https://www.fda.gov/media/78466/download)

> “HYQVIA is indicated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults.”
> “The starting dose and dosing frequency of HYQVIA is the same as the patient’s previous IGIV treatment. The typical dosing interval range in the clinical trial for HYQVIA was 2 to 4 weeks.”

Source: [HyQvia prescribing information (2026)](https://www.fda.gov/media/89844/download)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
